Connect with us

Technology

High Throughput Screening (HTS) Market to Grow by USD 19.9 Billion (2024-2028), Boosted by Rising R&D Investments, with AI Redefining Market Landscape – Technavio

Published

on

NEW YORK, Jan. 31, 2025 /PRNewswire/ — Report with market evolution powered by AI – The global high throughput screening (HTS) market size is estimated to grow by USD 19.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 12.12%  during the forecast period. Rise in R and D investments is driving market growth, with a trend towards increasing focus on promotional activities. However, shortage of trained healthcare professionals  poses a challenge. Key market players include Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc..

Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View Free Sample PDF

High Throughput Screening (HTS) Market Scope

Report Coverage

Details

Base year

2023

Historic period

2018 – 2022

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 12.12%

Market growth 2024-2028

USD 19.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

11.64

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 40%

Key countries

US, Japan, China, Germany, and France

Key companies profiled

Agilent Technologies Inc., Aurora Biomed Inc., Axxam Spa, Beckman Coulter Inc., Bio Rad Laboratories Inc., Biomat Srl, BMG LABTECH GmbH, Charles River Laboratories International Inc., Corning Inc., Danaher Corp., DIANA Biotechnologies s.r.o, HighRes Biosolutions, JSR Life Sciences LLC, Lonza Group Ltd., Merck KGaA, NanoTemper Technologies GmbH, PerkinElmer Inc., Sygnature Discovery Ltd., Tecan Trading AG, and Thermo Fisher Scientific Inc.

Market Driver

High-throughput screening (HTS) is a key trend in the life sciences sector, particularly in the areas of drug discovery and research for complex illnesses like cancer and neurological disorders. HTS allows for the rapid testing of large compound libraries using automated equipment such as robotic arms and microplate readers. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to analyze genomic data and chemical databases for target identification. Biotech startups and academic institutions are driving innovation in this field, with pharmaceutical corporations and research organizations collaborating to advance drug development. HTS is also used in stem cell research, toxicology, and open innovation models. HTS service providers offer instruments, software, and consumables to support this research. HTS is transforming the biopharmaceutical industry, enabling precision medicine and the repurposing of existing drugs for new indications. With advancements in technology, HTS is becoming more accessible to a wider range of organizations, including biotechnology startups and clinical trials. Despite these advancements, challenges remain, including false-positive findings and the need for specialized equipment maintenance. Overall, HTS is a vital tool in the global healthcare sector’s quest to develop new products and services for the detection and treatment of chronic diseases. 

The High Throughput Screening (HTS) market presents unique challenges for vendors due to its specialized nature and niche end-users. Brand and product visibility play a limited role in sales, and advertising and marketing are restricted. Key players in the industry recognize this issue and are promoting HTS through their websites and additional support materials. Thermo Fisher Scientific, for instance, provides explanatory documents, brochures, and interactive videos on YouTube to help end-users understand the technique better. Despite these efforts, there is a significant lack of awareness about HTS. Vendors must focus on improving their distribution networks to make these products readily available to end-users. 

Request Sample of our comprehensive report now to stay ahead in the AI-driven market evolution!

Market Challenges

High-throughput screening (HTS) is a crucial process in the biotechnology industry, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. The market for HTS is vast and diverse, with players including academic institutions, biotech startups, and pharmaceutical corporations. Challenges in this field include managing large data sets from compound libraries, dealing with false-positive findings, and maintaining specialized equipment. HTS involves the use of automation, robotics, and specialized instruments like microplate readers and high-resolution imaging systems. Data analytics is essential for making sense of the vast amounts of data generated. Machine learning and data management systems help in data organization, retrieval, integration, and storage. HTS is not just limited to pharmaceutical companies but also extends to the global healthcare sector, research organizations, and contract research organizations. Collaborative networks and HTS service providers play a significant role in driving innovation through open innovation models. HTS is also used in stem cell research, toxicology, and drug development. HTS involves various techniques like cell-based assays, lab-on-a-chip, and label-free technology. Biochemical screening and target identification are critical components of the HTS process. Drug repurposing initiatives, such as those from Relay Therapeutics, are gaining popularity in the biopharmaceutical industry due to their potential to bring new drugs to market faster and more cost-effectively. The HTS market is expected to grow significantly due to the increasing focus on precision medicine and the need for new drugs to address chronic diseases. Consumables, software, and services are essential products and services in the HTS market. The use of technology in HTS, such as automation and advanced detection techniques, is transforming the drug discovery process. Despite the challenges, the future of HTS looks promising, with advancements in technology and a growing focus on collaboration and open innovation models. The use of HTS in drug discovery and development is expected to revolutionize the way we approach complex illnesses and bring new treatments to market.In today’s fast-paced pharmaceutical and biotechnology industries, High Throughput Screening (HTS) has become a crucial tool for discovering new drugs and optimizing existing ones. However, the successful implementation of HTS relies heavily on the availability of skilled personnel. The shortage of trained professionals in this field can lead to non-compliance and improper screening of drug targets. Consequently, product failures and regulatory issues can result in significant financial losses for companies. This issue is particularly prevalent in developing countries, where the healthcare system lacks the necessary workforce to effectively utilize HTS technology. To mitigate this challenge, it is essential for organizations to invest in training and development programs for their staff, ensuring they have the necessary expertise to operate HTS equipment effectively and efficiently.

Discover how AI is revolutionizing market trends- Get your access now!

Segment Overview 

This high throughput screening (HTS) market report extensively covers market segmentation by  

Application 1.1 Target identification and validation1.2 Primary and secondary screening1.3 Toxicology assessment1.4 Stem cell researchEnd-user 2.1 Pharmaceutical and biotechnology companies2.2 Academic and research institutes2.3 CROsGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Target identification and validation-  The global high throughput screening (HTS) market is driven by the increasing need for target identification and validation in drug development. This process involves finding potential therapeutic targets for diseases or conditions without existing treatments or inadequate current options. Early and thorough target identification and validation establish a strong link to clinical trial success. Chronic diseases like cardiovascular diseases, cancer, and respiratory diseases, which have a high global prevalence, fuel the demand for new targets. Additionally, the growing pipeline for biological candidates, outsourcing from pharmaceutical companies, and regulatory agencies’ demand for accurate drug and process development details contribute to market expansion. Advanced bioinformatics tools, automated experimental designs, and AI/ML algorithms are enhancing target identification and validation, further boosting the segment’s growth. Consequently, these factors are expected to fuel the growth of the target identification and validation segment in the global high throughput screening market during the forecast period.

Download a Sample of our comprehensive report today to discover how AI-driven innovations are reshaping competitive dynamics

Research Analysis

High-throughput screening (HTS) is a critical technology in the global healthcare sector, enabling the rapid and efficient identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, often containing hundreds of thousands to millions of compounds, which are screened against disease targets using automated systems. These systems include robotic arms, microplate readers, and high-resolution imaging systems. Data analytics plays a crucial role in HTS, with data management systems, data storage, data organization, data retrieval, data integration, and chemical databases essential for processing and interpreting the vast amounts of data generated. Academic institutions, biotech startups, research organizations, and pharmaceutical corporations all contribute to the HTS market, with open innovation models facilitating collaboration and knowledge sharing. Drug repurposing, the process of discovering new uses for existing drugs, is also a significant application of HTS. The market for HTS is expected to grow significantly due to the increasing demand for new and effective treatments for various diseases.

Market Research Overview

High Throughput Screening (HTS) is a critical technology in the life sciences sector, enabling the rapid identification of potential drug candidates for complex illnesses such as cancer and neurological disorders. HTS utilizes compound libraries, automation, and specialized equipment like robotic arms, microplate readers, and high-resolution imaging systems to screen large numbers of compounds against specific targets. Data analytics plays a crucial role in HTS, with machine learning and data management systems used to organize, store, retrieve, integrate, and analyze genomic data and chemical databases. Collaborative networks and HTS service providers facilitate open innovation models and knowledge sharing among academic institutions, biotech startups, pharmaceutical corporations, and research organizations. Drug repurposing initiatives and biopharmaceutical industry leaders are leveraging HTS for precision medicine and target identification, while toxicology and stem cell research also benefit from this technology. The global healthcare sector continues to invest in HTS for drug discovery, clinical trials, and product development, driving the market for instruments, software, and consumables.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ApplicationTarget Identification And ValidationPrimary And Secondary ScreeningToxicology AssessmentStem Cell ResearchEnd-userPharmaceutical And Biotechnology CompaniesAcademic And Research InstitutesCROsGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/high-throughput-screening-hts-market-to-grow-by-usd-19-9-billion-2024-2028-boosted-by-rising-rd-investments-with-ai-redefining-market-landscape—technavio-302364447.html

SOURCE Technavio

Continue Reading

Technology

Canton Fair Buyers Alliance Launched as the 140th Edition Opens

Published

on

By

GUANGZHOU, China, Oct. 17, 2026 /PRNewswire/ — On October 15, the Canton Fair Buyers Alliance was officially launched at the Canton Fair Complex, marking a significant milestone as the fair celebrates the 70th anniversary of its founding.

More than 140 overseas buyers attended the launch ceremony, highlighting the fair’s enduring role as a bridge connecting global commerce with China’s export sector.

Speaking at the ceremony, Luís Vilariça, CEO of Joinco, Import & Export, Ltd., discussed his company’s long-standing relationship with the Canton Fair. Drawing on years of participation, he reflected on the growth opportunities created through cooperation with Chinese suppliers and highlighted the fair’s role in supporting international business development and global trade exchanges.

The ceremony also featured a joint declaration by alliance members. Representatives from five member companies read the statement in their respective native languages, underscoring the international character of the new organization. Additional members sent video congratulatory messages, joining the celebration and witnessing the official launch of the alliance.

The Canton Fair Buyers Alliance represents one of the fair’s key service innovations. Designed primarily for Fortune Global 500 companies, buyers from the world’s top 250 retailers and leading sourcing enterprises across a diverse range of markets, the alliance aims to offer members a platform for information sharing and resource coordination. The first cohort of alliance members includes 58 companies from 32 countries and regions across 5 continents. Through the alliance, members will gain access to a range of priority benefits spanning four major areas: services, events, resources and information.

 For more convenient attendance, please click here for pre-registration:

https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

View original content to download multimedia:https://www.prnewswire.com/news-releases/canton-fair-buyers-alliance-launched-as-the-140th-edition-opens-302911896.html

SOURCE Canton Fair

Continue Reading

Technology

Bioethanol from human hair – Indian start-up’s solution to rising prices of grains and sugar

Published

on

By

GUJARAT, India, Oct. 17, 2026 /PRNewswire/ — In what could be called the beginning of the 5G (fifth-generation) of bioethanol or non-cellulosic bioethanol or non-sugar-based biofuels, an Indian start-up, Techofest Global, based out of Gujarat, has developed its own, indigenous, and patented technology for the production of bioethanol from waste human hair. Such processes would significantly reduce the employment of sugars, grains, and agricultural residues, which form the classical first- and second-generation bioethanol feedstocks. As a result, the rising fuel-vs.-food/fodder debate is anticipated to reduce, and instead, ethanol produced from municipal/industrial waste, after trials, can supplement the current supply being used as blends with presently retailed fossil fuels (E20, E27, etc.). 

As stated by Dr. Ravi, the founder-CEO of Techofest Global, the strategic priority and the USP of the start-up is industrial symbiosis, which, typically, involves an ecosystem of up-cycling/valorising the effluents of an industry, thereby creating a value-chain for residues often lacking an end-of-life. With more than three decades of experience in designing customized nuclear fusion reactors for international programmes, such as ITER, JET/UKAEA and SST-1, Dr. Ravi, a seasoned mechanical engineer, spearheads the start-up’s patented technologies’ scale-up and commercialization.

Two biochemical engineers, Dr. Navnit – the former CTO, and Dr. Kabilan – the former CEO of Biomakerz, Chennai, are the brains behind the current technology/process portfolio of the joint-venture between Techofest Global and Biomakerz. They have been working on biorefineries’ process intensification for more than a decade. “Having foreseen the fuel-vs-fodder/food competition as early as the year 2015, we began developing techno-economically feasible and viable in-vitro metabolically-engineered bioprocesses for scaling-up ethanol production from municipal waste streams between 2019–2021”, says Navnit. After developing operational technologies for international biofuel organizations, serving process engineer roles with certain biorefineries-related OMC R&D’s of India, Dr. Navnit, presently works for a premier academic institution.

An on-going fermentation trial at the Techofest Global-Biomakerz JV’s R&D facility

Techofest Global has developed and tested, in its R&D JV’s pilot-facility of ~100-L, 3 innovative and cost-effective technologies, such as 5G ethanol production using human hair, used cooking oil (UCO), and enriched bio-methane production from disposed sanitary napkins.

“With massive CapEx and OpEx, 2G ethanol technology is facing a major commercialization bottleneck, owing to competition with food/livestock fodder, requirement of a cost-intensive pre-treatment procedure, and the requirement of cellulolytic cocktails, which have a poor recycle efficiency. The proprietary 5G SAFE process developed for the start-up circumvents the mentioned constraints, and instead, utilizes a single-stage saccharification followed by fermentation, and records over 85–90% biocatalyst recovery. Likewise, the proprietary SIM process for bio-methane production, exclusively developed for the start-up, is 2x faster with improved intermittent feeding cycles and continuous gas harvest”, says Navnit.

“With on-going pre-commercialization trials, the proprietary ethanol and bio-methane processes of ours are soon being commercialized”, says Ms. Bhumika, the co-founder and the corporate advisor of the start-up. Furthermore, Mr. Ronak pilots the organization’s global market entry and commercialization frontier.

Techofest Global’s veteran Principal Technology Advisors include: Dr VS Tripathi, former Joint Director, DRDE Gwalior, Dr B S Munjal, former Director, Structures and Thermal group, SAC/ISRO, Academician and Advisor CIKS-Dharohar, GTU, and Dr AV Santhanababu, former Scientist at Satish Dhawan Space Centre. With on-going R&D activities, Dr. Munjal says, “the start-up is striving to provide a unique solution along the lines of the Atmanirbhar and Viksit Bharat Vision 2047”.

Media Contact: www.techofestglobal.com; e-mail: info@techofestglobal.com; contact person: The PR team of Techofest Global.

Photo: https://mmx.prnewswire.com/media/MS2015507/Picture1.jpg?id=OA3024965&token=5vT9XuZXAG0yamsZlRrsBAiUapaplm73wYH8NIfU0xCtOlj76dueXcTw2Eb-3w

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/bioethanol-from-human-hair–indian-start-ups-solution-to-rising-prices-of-grains-and-sugar-302911813.html

Continue Reading

Technology

As AI Speeds Up Marketing, Louisville’s RedTag Bets on Strategy

Published

on

By

Independent agency unveils new brand and website, and co-hosts Louisville’s PROOF AI Workshop

LOUISVILLE, Ky., Oct. 17, 2026 /PRNewswire/ — RedTag, an independent Louisville-based marketing agency, this month unveiled new positioning, marking its evolution from a digital performance agency into a strategy-first marketing partner. The move comes as AI makes execution faster than ever, and RedTag is betting that strategy, not speed, is what will set businesses apart. Clients can now choose from outcome-based programs that best fit their marketing needs. 

“Clients don’t come to us needing more tactics. They come to us needing a path,” said Russ Renbarger, founder and CEO of RedTag. “Our new brand says out loud what our work has shown for years: We start with strategy and build everything on that foundation.”

RedTag built its reputation on high-performing paid digital campaigns. Over the years, the agency expanded into strategy, creative, video production and website development, giving clients one partner for the full scope of their marketing. Most recently, a team of automation specialists has integrated AI across the agency to speed up production and analysis, guided by an internal AI policy that keeps people accountable for quality. The time AI saves goes back into strategy: knowing what to say, who to say it to and why.

“Our best client relationships have always been partnerships, where we’re in the room when the big decisions get made,” said Alison Conway, chief client officer at RedTag. “This evolution is about bringing that strategic partnership to every client.”

On Oct. 14, RedTag co-hosted the PROOF AI Workshop with Slingshot, Vsimple and Advanced Business Solutions. The hands-on event gave Louisville business leaders practical experience applying AI to their own work. RedTag led the event’s AI in Marketing and Branding track, with four sessions ranging from AI search optimization to a playbook for adopting AI across an organization.

“AI can produce hundreds of ads in an afternoon, but it can’t tell you which one your brand actually needs and why,” Renbarger said. “The faster the tools get, the more valuable human-led strategy becomes.”

RedTag was named the agency of record for the Commonwealth of Kentucky in 2025. Its client list includes PGA of America, Castle & Key Distillery, Bourbon Barrel Foods, ShopCaterpillar and American Beverage Marketers. Since 2023, RedTag’s work has received two Emmy Awards and more than 35 ADDY and AIGA awards. The agency is a four-time Louisville Business First Fast 50 honoree and was named one of the 2026 Best Places to Work in Kentucky.

To learn more about its outcome-based programs, visit RedTag Programs

About RedTag

RedTag is an independent, strategy-first marketing agency based in Louisville, Kentucky. Established in 2008, the agency starts every engagement by understanding the goal before recommending tactics. With a foundation rooted in discovery, RedTag delivers full-scale marketing campaigns built around each client’s business goals. RedTag serves organizations across hospitality, sports, agriculture, government, retail and consumer packaged goods. Learn more at redtag.agency.

View original content to download multimedia:https://www.prnewswire.com/news-releases/as-ai-speeds-up-marketing-louisvilles-redtag-bets-on-strategy-302911869.html

SOURCE RED TAG LLC

Continue Reading

Trending